Effects of LIF Administration inmpl−/− Mice
| . | mpl+/+ . | mpl−/− . | ||
|---|---|---|---|---|
| Carrier . | LIF . | Carrier . | LIF . | |
| Spleen weight (mg) | 88 ± 37 | 96 ± 21 | 92 ± 34 | 128 ± 30* |
| Platelets (×10−6/mL) | 857 ± 200 | 1,431 ± 386† | 61 ± 18 | 103 ± 26† |
| Hematocrit (%) | 51 ± 3 | 50 ± 3 | 48 ± 3 | 45 ± 3 |
| WCC (×10−6/mL) | 4.1 ± 1.1 | 3.4 ± 1.4 | 3.7 ± 0.6 | 3.4 ± 0.6 |
| Megakaryocytes | ||||
| Bone marrow (per 30 hpf) | 118 ± 25 | 145 ± 25* | 7.9 ± 5.8 | 10.9 ± 4.8 |
| Spleen (per 60 hpf) | 26 ± 27 | 36 ± 24 | 0.4 ± 0.5 | 0.4 ± 0.5 |
| Megakaryocyte progenitor cells | ||||
| Bone marrow (×10−3 per femur) | 12.1 ± 3.3 | 16.4 ± 6.0 | 4.1 ± 1.5 | 3.7 ± 1.7 |
| Spleen (×10−3) | 8.7 ± 5.4 | 11.8 ± 5.9 | 2.6 ± 2.0 | 5.0 ± 4.7 |
| . | mpl+/+ . | mpl−/− . | ||
|---|---|---|---|---|
| Carrier . | LIF . | Carrier . | LIF . | |
| Spleen weight (mg) | 88 ± 37 | 96 ± 21 | 92 ± 34 | 128 ± 30* |
| Platelets (×10−6/mL) | 857 ± 200 | 1,431 ± 386† | 61 ± 18 | 103 ± 26† |
| Hematocrit (%) | 51 ± 3 | 50 ± 3 | 48 ± 3 | 45 ± 3 |
| WCC (×10−6/mL) | 4.1 ± 1.1 | 3.4 ± 1.4 | 3.7 ± 0.6 | 3.4 ± 0.6 |
| Megakaryocytes | ||||
| Bone marrow (per 30 hpf) | 118 ± 25 | 145 ± 25* | 7.9 ± 5.8 | 10.9 ± 4.8 |
| Spleen (per 60 hpf) | 26 ± 27 | 36 ± 24 | 0.4 ± 0.5 | 0.4 ± 0.5 |
| Megakaryocyte progenitor cells | ||||
| Bone marrow (×10−3 per femur) | 12.1 ± 3.3 | 16.4 ± 6.0 | 4.1 ± 1.5 | 3.7 ± 1.7 |
| Spleen (×10−3) | 8.7 ± 5.4 | 11.8 ± 5.9 | 2.6 ± 2.0 | 5.0 ± 4.7 |
Mean ± standard deviation of data from 7 to 11 mice in each group. Progenitor cell numbers were enumerated from stained semisolid agar cultures containing IL-3, SCF, and EPO and incubated in 5% CO2 in air at 37°C for 7 days.
P < .05.
P < .01 for comparison with carrier-injected controls of the same phenotype.